Brought to you by 
4-Antibody AG brings in CHF6mm via Series A; adds CHF17mm
18 Jan 2007
Executive Summary
Swiss therapeutic antibodies developer 4-Antibody AG raised CHF6mm ($4.9mm) in its Series A financing. The round included returning backers BioMedinvest AG, Grazia Equity, Life Sciences Partners, and Mulligan BioCapital.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Synthesis Technologies, Production Processes
-
Large Molecule
- Antibodies
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
4-Antibody AG brings in CHF6mm via Series A; adds CHF17mm
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice